Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Bjermer (Lund, Sweden). Estimating the number of patients’ needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study. 936

Member's Comments

No comment yet.

Related content which might interest you: Number needed to treat (NNT) with budesonide/formoterol to avoid one COPD exacerbation, with cost analysis of treatment Source: Eur Respir J 2004; 24: Suppl. 48, 540s Year: 2004 Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Number needed to treat: enigmatic results for exacerbations in COPD Source: Eur Respir J 2016; 47: 353-354 Year: 2016 Number needed to treat: enigmatic results for exacerbations in COPD Source: Eur Respir J 2016; 47: 354-355 Year: 2016 Number needed to treat: enigmatic results for exacerbations in COPD Source: Eur Respir J 2015; 45: 875-878 Year: 2015 Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Prediction models for exacerbations in different COPD patient populations: Results of five large databases Source: International Congress 2016 – COPD and asthma COPD overlap syndrome (ACOS): novelties in terms of prevalence, risk factors, and prognosis in COPD Year: 2016 Frequency of exacerbations in patients with COPD: an analysis of the SPIROMICS cohort Source: International Congress 2017 – COPD: latest insights into the management of patients Year: 2017 A global survey conducted to determine frequency of exacerbations in COPD patients Source: Annual Congress 2013 –COPD treatment Year: 2013 Early occurrence of any COPD exacerbation predicts further higher risk of moderate/severe exacerbations regardless of recording tool: the FLAME study Source: International Congress 2017 – Management of COPD Year: 2017 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Analysis of the frequency of COPD exacerbations in the ’real-life’ DACCORD study over a 2 year period Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 Methods for therapeutic trials in COPD: lessons from the TORCH trial Source: Eur Respir J 2009; 34: 1018-1023 Year: 2009 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Real-life COPD patients compared to large trial populations: An UNLOCK external validity study Source: Annual Congress 2013 –Management of respiratory diseases in primary care Year: 2013 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system Year: 2016